Journal of Clinical Lipidology
Volume 2, Issue 4 , Pages 237-247 , August 2008

Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein–deficiency states

  • Raul D. Santos, MD, PhD

      Affiliations

    • Lipid Clinic, Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil
    • ,
  • Bela F. Asztalos, PhD

      Affiliations

    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, and Tufts University School of Medicine, 711 Washington Street, Boston, MA 02111, USA
    • ,
  • Lilton R.C. Martinez, MD

      Affiliations

    • Lipid Clinic, Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil
    • ,
  • Marcio H. Miname, MD

      Affiliations

    • Lipid Clinic, Heart Institute (InCor) University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil
    • ,
  • Eliana Polisecki, PhD

      Affiliations

    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, and Tufts University School of Medicine, 711 Washington Street, Boston, MA 02111, USA
    • ,
  • Ernst J. Schaefer, MD

      Affiliations

    • Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, and Tufts University School of Medicine, 711 Washington Street, Boston, MA 02111, USA
    • Corresponding Author InformationCorresponding author.

Received 18 January 2008 ,Accepted 8 June 2008.

References 

  1. Schaefer EJ, Levy RI, Anderson DW, Danner RN, Brewer HB, Blackwelder WC. Plasma-triglycerides in regulation of HDL-cholesterol levels. Lancet. 1978;2:391–393
  2. Jahn CE, Schaefer EJ, Taam L, Hoofnagel J, Jones EA, Brewer HB. Lipoprotein abnormalities in primary biliary cirrhosis: association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology. 1985;89:1266–1278
  3. Goldberg RB, Mendez AJ. Severe acquired (secondary) high-density lipoprotein deficiency. J Clin Lipidol. 2007;1:41–56
  4. Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry. 2002;41:2089–2096
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  6. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991;67:1185–1189
  7. Genest JJ, Martin-Munley S, McNamara JR, et al. Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025–2033
  8. Genest JJ, Bard JM, Fruchart JC, Ordovas JM, Schaefer EJ. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb. 1993;13:1728–1737
  9. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418
  10. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events (VA-HIT: a randomized controlled trial). JAMA. 2001;285:1585–1591
  11. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease (Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)). Arch Intern Med. 2002;162:2597–2604
  12. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB. Plasma apolipoprotein A-I absence associated with marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis. 1982;2:16–26
  13. Schaefer EJ. The clinical, biochemical, and genetic features in familial disorders of high density lipoprotein deficiency. Arteriosclerosis. 1984;4:303–322
  14. Engel WK, Dorman JD, Levy RI, Fredrickson DS. Neuropathy in Tangier disease (Alpha-lipoprotein deficiency manifesting as familial recurrent neuropathy and intestinal lipid storage). Arch Neurol. 1967;17:1–9
  15. Ferrans VJ, Fredrickson DS. The pathology of Tangier disease (A light and electron microscopic study). Am J Pathol. 1975;78:101–158
  16. Assmann G, Herbert PN, Fredrickson DS, Forte T. Isolation and characterization of an abnormal high density lipoprotein in Tangier Disease. J Clin Invest. 1977;60:242–252
  17. Schaefer EJ, Ordovas JM, Law S, et al. Apolipoprotein A-I and C-III deficiency, variant II. J Lipid Res. 1985;26:1089–1101
  18. Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ. Familial apolipoprotein A-I, C-III, and A-IV deficiency with marked high density lipoprotein deficiency and premature atherosclerosis due to a deletion of the apolipoprotein A-I, C-III, and A-IV gene complex. J Biol Chem. 1989;264:16339–16342
  19. Norum RA, Lakier JB, Goldstein S, et al. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary artery disease. N Engl J Med. 1982;306:1513–1519
  20. Karathanasis SK, Norum RA, Zannis VI, Breslow JL. An inherited polymorphism in the human apolipoprotein A-I gene locus related to the development of atherosclerosis. Nature. 1983;301:718–720
  21. Karathanasis SK, Ferris E, Haddad EA. DNA inversion within the apolipoprotein AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. Proc Natl Acad Sci U S A. 1987;84:7198–7202
  22. Beher WT, Gabbard A, Norum RA, Stradnieks S. Effect of blood high density lipoprotein cholesterol concentration on fecal steroid excretion in humans. Life Sci. 1983;32:2933–2937
  23. Forte TM, Nichols AV, Krauss RM, Norum RA. Familial apolipoprotein AI and apolipoprotein CIII deficiency (Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis). J Clin Invest. 1984;74:1601–1613
  24. Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI (Evidence that apoCIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo). J Clin Invest. 1986;78:1287–1295
  25. Subbaiah PV, Norum RA, Bagdade JD. Effect of apolipoprotein activators on the specificity lecithin:cholesterol acyltransferase: determination of cholesteryl esters formed in A-I/C-III deficiency. J Lipid Res. 1991;32:1601–1609
  26. Bekaert ED, Alaupovic P, Knight-Gibson CS, Laux MJ, Pelachyk JM, Norum RA. Characterization of apoA-I and apoB containing lipoprotein particles in a variant of familial apolipoprotein A-I deficiency with planar xanthomas: the metabolic significance of LP-A-II particles. J Lipid Res. 1991;32:1587–1599
  27. Hiasa Y, Maeda T, Mori H. Deficiency of apolipoproteins A-I and C-III and severe coronary artery disease. Clin Cardiol. 1986;9:349–352
  28. Matsunaga T, Hiasa Y, Yanagi H, et al. Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1991;88:2793–2797
  29. Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein deficiency in a family with analphalipoproteinemia. J Clin Invest. 1994;93:223–229
  30. Ng DS, O'Connor PW, Mortimer CB, Leiter LA, Connelly PW, Hegele RA. Case report: retinopathy and neuropathy associated with complete apolipoprotein A-I deficiency. Am J Med Sci. 1996;312:30–33
  31. Santos RD, Schaefer EJ, Asztalos BF, et al. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J Lipid Res. 2008;46:349–357
  32. Matsunaga A, Sasaki J, Han H, et al. Compound heterozygozity for an apolipoprotein AI gene promoter mutation and a structural nonsense mutation with apolipoprotein deficiency. Arterioscler Thromb Vasc Biol. 1999;19:348–355
  33. Ikewaki K, Matsunaga A, Han H, et al. A novel two nucleotide deletion in the apolipoprotein A-I gene, apoA-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease. Atherosclerosis. 2004;172:39–45
  34. Deeb SS, Cheung MC, Peng R, et al. A mutation in the apolipoprotein A-I gene. J Biol Chem. 1991;266:13654–13660
  35. Pisciotta L, Miccoli R, Cantafora A, et al. Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency. Atherosclerosis. 2003;167:335–345
  36. Fredrickson DS, Altrocchi PH, Avioli LV, Goodman DS, Goodman HC. Tangier disease. Ann Intern Med. 1961;55:1016–1031
  37. Schaefer EJ, Zech LA, Schwartz DS, Brewer HB. Coronary heart disease prevalence and other clinical features in familial high density lipoprotein deficiency (Tangier disease). Ann Intern Med. 1980;93:261–266
  38. Serfaty-Lacrosniere C, Lanzberg A, Civeira F, et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis. 1994;107:85–98
  39. Chu FC, Kuwabara T, Cogan PG, Schaefer EJ, Brewer HB. Ocular manifestations of familial high density lipoprotein deficiency (Tangier disease). Arch Opthalmol. 1979;97:1926–1928
  40. Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, Schaefer EJ. Subpopulations of high-density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis. 2001;156:217–225
  41. Rogler G, Trumbach B, Klima B, Lackner KJ, Schmitz G. HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Arterioscler Thromb Vasc Biol. 1995;15:683–690
  42. Francis GA, Knopp RH, Oram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J Clin Invest. 1995;96:78–87
  43. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352–355
  44. Langmann T, Klucken J, Reil M, et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Comm. 1999;257:29–33
  45. Brooks A, Marcil M, Clee SM, et al. Mutation in ABC1 in Tangier disease and familial high density lipoprotein. Nature Gen. 1999;22:336–345
  46. Bodzioch M, Orso E, Klucken J, et al. The gene encoding ATP binding cassette transporter 1 is mutated in Tangier disease. Nature Gen. 1999;22:347–351
  47. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP binding cassette transporter 1. Nature Gen. 1999;22:352–355
  48. Brousseau ME, Schaefer EJ, Dupuis J, et al. Novel mutations in the gene encoding ATP-binding cassette 1 in four Tangier disease kindreds. J Lipid Res. 2000;41:433–441
  49. Brousseau ME, Eberhart GP, Dupuis J, et al. Cellular cholesterol efflux in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J Lipid Res. 2000;41:1125–1135
  50. Schaefer EJ, Brousseau ME, Diffenderfer MR, et al. Cholesterol and apolipoprotein B metabolism in Tangier disease. Atherosclerosis. 2001;159:231–236
  51. Norun KR, Gjone E. Familial plasma lecithin cholesterol acyl transferase deficient (Biochemical study if a new inborn error of metabolism). Scand J Clin Lab Invest. 1967;20:231–235
  52. Calabresi L, Pisciotta L, Constantin A, et al. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol. 2005;25:1972–1978
  53. Asztalos BF, Schaefer EJ, Horvath KV, et al. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res. 2007;48:592–599
  54. Asztalos BF, De la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1 and SRB1-mediated cholesterol efflux. J Lipid Res. 2005;46:2246–2253
  55. Asztalos BF, Cupples LA, Demissie S, et al. High density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants in the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24:2181–2187
  56. Asztalos BF, Collins D, Cupples LA, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25:2185–2191
  57. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol. 2003;23:847–852

PII: S1933-2874(08)00263-8

doi: 10.1016/j.jacl.2008.06.002

Journal of Clinical Lipidology
Volume 2, Issue 4 , Pages 237-247 , August 2008

Article Tools

* Image Usage & Resolution